Loading company…
Spatomics develops tools and platforms for single-cell spatial multi-omics.
Spatomics develops instruments and an end-to-end platform for single-cell spatial multi-omics. Its instrument handles tissue section preparation, antigen repair, staining, imaging, and image pre-processing. The company was founded in 2022 in Jiangsu, China, by CEO Rui Zheng, and has commercial collaborations with spatial histology CROs and reagent companies. In December 2025, it raised venture funding from Yihua Capital, Nanjing Jiangbei Tunzhi Biomedical Venture Capital Partnership (Limited Partnership), and K2VC.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in